INCATE

Less than a week left! Apply for PACE 2025 Antibacterial Therapeutics funding — up to £1M per project (total £6M).

Open worldwide | Focus: drug-resistant Gram-negative infections.

🗓️ Deadline: 5 Nov, 23:59 UK
➡️ buff.ly/cBfzdLN

#AMR #Innovation #Funding

Heading to @bactivac.bsky.social Birmingham next week? INCATE will be there!

Meet our colleague Peter Seiler and learn how INCATE supports vaccine projects tackling AMR. Let’s connect and drive impact together!

#BactiVacEvents #AMR #VaccineDevelopment

💥 Our October Newsletter is out! 💥
- INCATE's first report (2021-2024)
- AMR Conference: poster abstract open
- Milestones from the community
🚀 ...and more!

Read all about it in INCATE's Newsletter ➡ lnkd.in/eSp2K9Jv

Haven't you subscribed yet?
Don't fall behind, subscribe here ➡ lnkd.in/dxq4JtMt

🔴 Live TODAY!

Join our #REVIVE webinar with Adrian Egli (University of Zürich) & Javier Fernández Domínguez (Pragmatech AI Solutions) on how AI can help detect and predict antimicrobial resistance.

🗓️17:00–18:30 CET

👉 Join here: go.bsky.app/redirect?u=h...

#AMR #Antibiotics #AI #REVIVE

Big milestone for INCATE!

Our first report 2021–2024 is out: a journey of bridging academia & industry, supporting ventures, and turning science into impact.

More than a report: a celebration of collaboration, perseverance, and shared purpose.

Read it here ➡️ www.incate.net/celebrating-...

Kicking off the week with big news!

Basilea Pharmaceutica is once again sponsoring the Poster Competition at the 10th AMR Conference 2026.

🗓️ Abstracts submission deadline: Jan 7 2026

Info & submission ➡️ amr-conference.com/call-for-abs...

‘I fear we are sitting on a time bomb.’ Scientists debate mass distribution of antibiotics in Africa Prophylactic use of azithromycin saves vulnerable children’s lives, but could trigger antibiotic resistance

Can azithromycin save lives in Africa — without accelerating AMR?
This article explores the dilemma: prevention vs. resistance.
At INCATE, we believe innovation & stewardship must go hand in hand to protect both lives & the antibiotics we rely on.

Read more buff.ly/f6wRu8n

#AMR #GlobalHealth

Heading to Lyon for #I4ID2025?

Our colleague Derry Mercer will join the Scientific Advisory Board — come say hi!

I4ID brings together leaders from industry, academia & clinical research to advance innovation against infectious diseases & AMR.

📅 Nov 13–14, 2025
📍 ENS Lyon
➡️ i4id.org/program/

smartbax announces a €4.7 M Pre-Series A round to advance novel antibiotic compound through preclinical stage Lead antibacterial compound against a novel target in Gram-negative bacteria validated in infection modelsProgressing a platform of small-molecule...

Great news from smartbax — they’ve raised €4.7M Pre-Series A to advance their novel antibiotic through preclinical development!

We’re proud at INCATE to have supported them early on and thrilled to see their progress in the fight against #AMR.

Read more 👉 www.globenewswire.com/news-release...

AMR kills 1.27M people each year — we urgently need new solutions. On #WorldPhageDay, we celebrate phages: nature’s powerful allies against bacteria. At INCATE, we support innovators bringing phage therapies to life. Working on one? We want to hear from you! #AMR #Phage

Global antibiotic resistance surveillance report 2025: summary A summary of a new WHO report presenting a global analysis of antibiotic resistance prevalence and trends, drawing on more than 23 million bacteriologically confirmed cases of bloodstream infections, ...

The new WHO #AMR report shows 1 in 6 bacterial infections are now resistant to antibiotics — and rising fast.

At INCATE, we know AMR innovation isn’t optional, it’s urgent.
The world needs new antimicrobials — and we’re helping make that happen.

Read here ➡️ www.who.int/publications...

🚀 Getting ready to fundraise? Don’t miss Get Fundraising-Ready: Lawyers’ Insights on Due Diligence with Dr. Umberto Milano

🗓️ Oct 30
🕓 4–5pm CET
📍 Online

Hosted by Peak Spirit Academy & Viopas Venture Consulting.

Registration ➡️ events.teams.microsoft.com/event/f9e160...

Have you signed up to our newsletter yet?

Get expert insights, breaking news, and key updates delivered straight to your inbox.

Sign up for our newsletter now ➡️ buff.ly/qCI5lpY

Don't fall behind!

A randomized trial of simultaneous versus sequential pneumococcal vaccination in elderly To evaluate whether simultaneous vaccination of the 13-valent pneumococcal conjugate vaccine (PCV13) and the 23-valent polysaccharide vaccine (PPSV23) elicits higher antigen-specific memory B cell…

PCV13 + PPSV23 in adults 60+: Together is safe, but sequential gives stronger long-term immunity. Supports current STIKO guidance.

Read more ➡️

The AMR Conference 2026 Poster Call is open!

AMR Scientists: submit your abstract, share your innovation, and compete for poster prizes of up to €1,000. Don’t miss your chance to be part of the leading AMR event in Basel, March 2026.

📅 Deadline: Jan 7, 2026
Details: ➡️ buff.ly/Mjo5VLj

BBC Audio | The Documentary Podcast | The social lives of bacteria The microscopic dramas of bacterial loners, crowd-lovers, backstabbers and do-gooders

Did you know bacteria have social lives? Who cooperates, cheats, or backstabs — even a microbial Sopranos? Dr. Sally Le Page explores these microbial dramas and their impact on health & the environment.

Listen here ➡️

The German Center for Infection Research establishes a new funding initiative | German Center for Infection Research The German Center for Infection Research (DZIF) is launching the DZIF Start-up Fund, a new funding initiative to support spin-offs in translational infection research.

DZIF Start-up Fund: Support for spin-offs in infection research with mentoring + up to €500K funding. Focus: preventive & therapeutic anti-infectives. Apply by Nov 30, 2025!

More info ➡️

AI in antibiotics: not the future, but the present. Machine learning is helping discover new drugs against resistant bacteria like MRSA, shaping next-gen therapeutics. Essential in the fight against AMR.

Read more ➡️ buff.ly/6sXIcTA

Interested in the PACE-AMR 2025 Antibacterial Therapeutics Funding Call?
Don’t miss the informational webinar TOMORROW!

📅 Date: 8 October
⏰ Time: 4pm CEST (3pm BST)
⏳ Application deadline: 5 November

Get all the details you need to prepare a strong application.

Register here ➡️ buff.ly/ST74qY3

“Treatment with bacteriophages can combat antibiotic-resistant infections, but Swiss patients lack access” It is not only antibiotics but also certain viruses – known as bacteriophages – that can kill off pathogenic bacteria. However, Switzerland lacks the legal framework for the use of these viruses in…

ETH Zürich spoke with Alexander Harms on phage therapy’s promise—and why Swiss patients lack access due to missing legal frameworks. Policy + science must align for wider use.

Full interview ➡️

Congrats to Prof. Urs Jenal (@NCCR AntiResist) & the Tim Tolker-Nielsen Lab (Univ. of Copenhagen) on winning the Novo Nordisk Foundation Catalyst Grant 2025 for developing new anti-biofilm drugs against bacterial pathogens.

October is #BreastCancerAwareness Month.
In 2022: 2.3M women diagnosed, 670K lost.

But in 2025, many cancer patients face another threat: drug-resistant infections. AMR casts a growing shadow over oncology.

Read more ➡️ www.incate.net/when-cancer-...

The fight on non-communicable diseases and drug resistance Drug resistance threatens medical progress. Fighting both antimicrobial resistance and non-communicable diseases is key to protecting global health gains.

The UN spotlighted cancer, diabetes & heart disease last week. But progress on NCDs won’t hold if we ignore #AMR.
Resistant infections put vulnerable patients at even greater risk.

Why NCDs & AMR go together ➡️ www.weforum.org/stories/2025...

📢 Big moment for the AMR community!

On 17 Nov 2025, the SPEARHEAD Event lands in Zurich (+ online)
Think global leaders, fresh solutions, hands-on workshops — all focused on sustaining the fight AMR.

If AMR is on your radar, don't miss it!

Register now ➡️ www.swissre.com/reinsurance/...

CDC Report Finds Sharp Rise in Dangerous Drug-Resistant Bacteria A CDC report found a dramatic increase in a dangerous type of drug-resistant bacteria.

CDC warns: drug-resistant bacteria (NDM-CRE) infections up 460% in 4 years.
They resist top antibiotics + spread fast in hospitals.
AMR isn’t tomorrow’s challenge — it’s here now.

Read here ➡️ www.cdc.gov/media/releas...

The UK’s new AMR Action Plan shows progress—campaigns, surveillance, stewardship & innovation incentives.

AMR still a chronic global risk.

❓ Where should collaboration focus most: innovation, stewardship, or access?

Read here ➡️ www.gov.uk/government/p...

Join ERA4TB for the "Innovating Access: Tackling Anti-Microbial Resistance Through Policy and Partnerships" webinar featuring experts from NICE and the @who.int .
For professionals in AMR, TB, health policy, drug dev & HTA.

🗓️Oct. 8 at 2pm CET
📍 Online | Register ➡️ meetnice.zoom.us/webinar/regi...

💥 Our September Newsletter is out! 💥
- New Stage II winner
- New INCATE partnership
- Milestones from portfolio ventures
🚀 ...and more!

Read Newsletter ➡ 6s05i.r.a.d.sendibm1.com/mk/mr/sh/Oyc...

Haven't you subscribed yet? Don't fall behind, subscribe here ➡https://www.incate.net/contact/

Brigid Bio, a @uniofaberdeen.bsky.social spin-out, has been awarded INCATE Stage II support!

They’re developing antibody-based therapies to fight invasive fungal infections — a deadly and growing resistance challenge.

Congrats to the Brigid Bio team!

Read more ➡️ www.incate.net/brigid-bio-a...

Thank you for your feedback, we are totally glad you liked it and found it useful. We'll be organising another one soon, stay tuned!